Haleon PLC Asset Resilience Ratio
Haleon PLC asset resilience ratio. Haleon PLC (HLN) has an Asset Resilience Ratio of -0.02% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HLN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Haleon PLC (2019–2023)
Asset resilience ratio of Haleon PLC from 2019 to 2023. This chart shows how Haleon PLC's Asset Resilience Ratio has changed over time. Read Haleon PLC debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Haleon PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Haleon PLC's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-6.00 Million | -0.02% |
| Total Liquid Assets | GBX-6.00 Million | -0.02% |
Asset Resilience Insights
- Limited Liquidity: Haleon PLC maintains only -0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Haleon PLC Industry Peers by Asset Resilience Ratio
Compare Haleon PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Haleon PLC Asset Resilience Ratio by Year (2019–2023)
Haleon PLC asset resilience ratio by year from 2019 to 2023. The table below shows the annual Asset Resilience Ratio data for Haleon PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.11% | GBX-36.00 Million ≈ $-4.38K |
GBX34.05 Billion ≈ $4.14 Million |
-0.33pp |
| 2022-12-31 | 0.22% | GBX78.00 Million ≈ $9.49K |
GBX34.81 Billion ≈ $4.24 Million |
+0.22pp |
| 2021-12-31 | 0.00% | GBX1.00 Million ≈ $121.67 |
GBX34.45 Billion ≈ $4.19 Million |
0.00pp |
| 2020-12-31 | 0.00% | GBX1.00 Million ≈ $121.67 |
GBX34.13 Billion ≈ $4.15 Million |
+0.00pp |
| 2019-12-31 | 0.00% | GBX1.00 Million ≈ $121.67 |
GBX35.71 Billion ≈ $4.34 Million |
-- |
About Haleon PLC
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene… Read more